These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 33249657

  • 1. Histological characteristics of lung adenocarcinoma with uncommon actionable alterations: special emphasis on MET exon 14 skipping alterations.
    Hayashi T, Kohsaka S, Takamochi K, Kishikawa S, Ikarashi D, Sano K, Hara K, Onagi H, Suehara Y, Takahashi F, Saito T, Nakatsura T, Kitano S, Suzuki K, Yao T.
    Histopathology; 2021 Jun; 78(7):987-999. PubMed ID: 33249657
    [Abstract] [Full Text] [Related]

  • 2. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
    Guo R, Berry LD, Aisner DL, Sheren J, Boyle T, Bunn PA, Johnson BE, Kwiatkowski DJ, Drilon A, Sholl LM, Kris MG.
    J Thorac Oncol; 2019 Sep; 14(9):1666-1671. PubMed ID: 31228623
    [Abstract] [Full Text] [Related]

  • 3. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
    Saigi M, McLeer-Florin A, Pros E, Nadal E, Brambilla E, Sanchez-Cespedes M.
    Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
    [Abstract] [Full Text] [Related]

  • 4. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
    Lee GD, Lee SE, Oh DY, Yu DB, Jeong HM, Kim J, Hong S, Jung HS, Oh E, Song JY, Lee MS, Kim M, Jung K, Kim J, Shin YK, Choi YL, Kim HR.
    J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
    [Abstract] [Full Text] [Related]

  • 5. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
    Wang SXY, Zhang BM, Wakelee HA, Koontz MZ, Pan M, Diehn M, Kunder CA, Neal JW.
    Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
    [Abstract] [Full Text] [Related]

  • 6. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
    Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin CM, Kris MG, Arcila ME, Lockwood WW, Drilon A, Ladanyi M, Somwar R.
    Clin Cancer Res; 2019 Feb 15; 25(4):1248-1260. PubMed ID: 30352902
    [Abstract] [Full Text] [Related]

  • 7. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
    Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian GP, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.
    J Thorac Oncol; 2016 Sep 15; 11(9):1493-502. PubMed ID: 27343443
    [Abstract] [Full Text] [Related]

  • 8. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
    Kwon D, Koh J, Kim S, Go H, Kim YA, Keam B, Kim TM, Kim DW, Jeon YK, Chung DH.
    Lung Cancer; 2017 Apr 15; 106():131-137. PubMed ID: 28285687
    [Abstract] [Full Text] [Related]

  • 9. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG.
    Cancer; 2015 Feb 01; 121(3):448-56. PubMed ID: 25273224
    [Abstract] [Full Text] [Related]

  • 10. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
    Kim EK, Kim KA, Lee CY, Kim S, Chang S, Cho BC, Shim HS.
    Clin Lung Cancer; 2019 Jan 01; 20(1):e123-e132. PubMed ID: 30391211
    [Abstract] [Full Text] [Related]

  • 11. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA, Geurts-Giele WRR, von der TJH, Meijssen IC, Dinjens WNM, Aerts JGJV, Dingemans AMC, Lolkema MP, Paats MS, Dubbink HJ.
    Lung Cancer; 2020 Feb 01; 140():46-54. PubMed ID: 31862577
    [Abstract] [Full Text] [Related]

  • 12. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
    Li Y, Gao L, Ma D, Qiu T, Li W, Li W, Guo L, Xing P, Liu B, Deng L, Fu J, Li J, Yu Y, Ying J.
    Lung Cancer; 2018 Aug 01; 122():113-119. PubMed ID: 30032818
    [Abstract] [Full Text] [Related]

  • 13. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
    Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA.
    Cancer Discov; 2015 Aug 01; 5(8):850-9. PubMed ID: 25971938
    [Abstract] [Full Text] [Related]

  • 14. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics.
    Salimian KJ, Fazeli R, Zheng G, Ettinger D, Maleki Z.
    Acta Cytol; 2018 Aug 01; 62(2):79-84. PubMed ID: 29320776
    [Abstract] [Full Text] [Related]

  • 15. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
    Yeung SF, Tong JHM, Law PPW, Chung LY, Lung RWM, Tong CYK, Chow C, Chan AWH, Wan IYP, Mok TSK, To KF.
    J Thorac Oncol; 2015 Sep 01; 10(9):1292-1300. PubMed ID: 26098749
    [Abstract] [Full Text] [Related]

  • 16. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.
    Lee JK, Madison R, Classon A, Gjoerup O, Rosenzweig M, Frampton GM, Alexander BM, Oxnard GR, Venstrom JM, Awad MM, Schrock AB.
    JCO Precis Oncol; 2021 Sep 01; 5():. PubMed ID: 34476332
    [Abstract] [Full Text] [Related]

  • 17. Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
    Marks JA, Gandhi N, Halmos B, Marmarelis ME, Yeon Kim S, Bazhenova L, Ramalingam SS, Xiu J, Walker P, Oberley MJ, Ma PC, Liu SV.
    Lung Cancer; 2024 Oct 01; 196():107935. PubMed ID: 39241297
    [Abstract] [Full Text] [Related]

  • 18. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.
    Le X, Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D, Tsao A, Hong D, Raymond V, Paik P, Zhang J, Heymach JV.
    JCO Precis Oncol; 2021 Oct 01; 5():. PubMed ID: 34957368
    [Abstract] [Full Text] [Related]

  • 19. Reciprocal expression of trefoil factor-1 and thyroid transcription factor-1 in lung adenocarcinomas.
    Matsubara D, Yoshimoto T, Soda M, Amano Y, Kihara A, Funaki T, Ito T, Sakuma Y, Shibano T, Endo S, Hagiwara K, Ishikawa S, Fukayama M, Murakami Y, Mano H, Niki T.
    Cancer Sci; 2020 Jun 01; 111(6):2183-2195. PubMed ID: 32237253
    [Abstract] [Full Text] [Related]

  • 20. Transcription start site-level expression of thyroid transcription factor 1 isoforms in lung adenocarcinoma and its clinicopathological significance.
    Sano K, Hayashi T, Suehara Y, Hosoya M, Takamochi K, Kohsaka S, Kishikawa S, Kishi M, Saito S, Takahashi F, Kaneko K, Suzuki K, Yao T, Ishijima M, Saito T.
    J Pathol Clin Res; 2021 Jul 01; 7(4):361-374. PubMed ID: 34014042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.